Biotechnology · Nasdaq
MRNAModerna, Inc.
- Last close
- $223.37 -3.5%
- 52-week range
- $22.28 to $280.80
- Market cap
- $90.4B
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Stock price
Valuation vs its own history since 2018
Above its median since 2018 on 1 multiple
Where each multiple sits today inside its own range since 2018, measured at every quarter end. The thin tick is the median.
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.
Valuation
- P/E
- n/aNo earnings
- Earnings yield
- -3.2%
- Price / sales
- 35.8x
- Price / book
- 13.2x
- Price / operating cash flow
- n/a
- EV / EBITDA
- n/a
- EV / sales
- 33.7x
- Free cash flow yield
- -2.2%
n/a: Not reported
Profitability
- Gross margin
- 28.0%
- Operating margin
- -116%
- Net margin
- -110%
- Return on equity
- -40.8%
- Return on capital
- -33.9%
Growth per year
- Revenue, 3 years
- -53.4%
- Revenue, 5 years
- +19.3%
- Revenue, 9 years
- +37.8%
- EPS, 3 years
- n/aNot meaningful (a loss in the window)
Balance sheet
- Cash and investments
- $5.17B
- Total debt
- n/a
- Net cash
- $5.17B
- Debt / equity
- n/a
- Current ratio
- 3.62x
n/a: No debt reported
Shares and dividend
- Shares outstanding
- 405M
- Share count, 5 years
- +2.1%
- Beta, 1 year
- 2.37
- Dividend yield
- n/a
- Dividend per share, TTM
- n/a
- Payout ratio
- n/a
n/a: No dividend
Ten years of the business
Last 39 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2016 to 2025.
Where the revenue comes from
Collaboration Arrangement Including Arrangements With Affiliate went from 2% to 1% of revenue in 3 years
Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.
| Product line | Revenue | Share | vs FY24 |
|---|---|---|---|
| Product Sales | $1.82B | 93.5% | -42% |
| St and Ready Manufacturing Revenue | $80.0M | 4.1% | n/a |
| Grant | $22.0M | 1.1% | -41% |
| Collaboration Arrangement Including Arrangements With Affiliate | $13.0M | 0.7% | -73% |
| License and Royalty | $11.0M | 0.6% | -74% |
| RSV | $8.00M | 0.4% | -68% |
Biotechnology peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| ONC BeOne Medicines Ltd. | $619B | +33% | 17.8% | 689x | 93.6x | Not enough history |
| ABBV AbbVie Inc. | $521B | +11% | 32.2% | 50.8x | 7.9x | 72nd percentile |
| AMGN Amgen Inc | $252B | +8% | 32.4% | 27.0x | 6.5x | 78th percentile |
| GILD Gilead Sciences, Inc. | $208B | +7% | -7.6% | No earnings | 6.7x | No earnings |
| VRTX Vertex Pharmaceuticals Inc / Ma | $137B | +10% | 33.2% | 34.7x | 10.5x | 71st percentile |
| MRNA Moderna, Inc. | $90.4B | +13% | -116% | No earnings | 35.8x | No earnings |
The company
- Sector
- Health Care
- Industry
- Biotechnology
- CEO
- Stéphane Bancel
- Employees
- 5,800 (as of 2024)
- Founded
- 2010
- Headquarters
- Cambridge, MA
- Fiscal year ends
- December
- Website
- modernatx.com
What it does
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Description from Wikipedia (CC BY-SA).
Around the numbers
What the rest of EdgeStacker knows about MRNA.
Held by 491 active funds. Crowd level: crowd building, 3 rising quarters.
Open the Smart money tab